Physician profile
David B Herman
NPI 1205945417
$3,209.88
in general payments reported to CMS, 2019-2025
24 companies · $256 in 2025
The $256 reported for 2025 was more than what 80% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $159 · 2021: $193 · 2022: $533 · 2023: $766 · 2024: $776 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $607.31 | 2022-2025 | Azstarys |
| Pfizer INC. | $332.45 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $330.44 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, Lp | $309.77 | 2019-2024 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $290.81 | 2019-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $177.22 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Seqirus USA INC | $177.17 | 2022-2025 | Flucelvax, Flucelvax Quadrivalent |
| Shire North American Group INC | $136.56 | 2019 | |
| Kaleo, INC. | $125.76 | 2019-2024 | Auvi-Q |
| Sobi, INC | $105.75 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.13 | 2020-2022 | |
| Sanofi Pasteur INC. | $74.62 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $73.72 | 2024-2025 | Qelbree |
| Cranial Technologies, INC | $70.08 | 2021-2025 | Doc Band |
| Tris Pharma INC | $61.74 | 2023-2024 | Dyanavel Xr |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $41.42 | 2019-2020 | |
| Genentech USA, INC. | $38.17 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $34.68 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $34.59 | 2024 | Ycanth |
| Novartis Pharmaceuticals Corporation | $32.59 | 2019 | |
| Abbvie INC. | $26.53 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $23.31 | 2023 | Evusheld |
| Arbor Pharmaceuticals, INC. | $14.63 | 2019 | |
| Noven Therapeutics, LLC | $14.43 | 2024 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.